RAIMONDO, ANNUNZIATA
 Distribuzione geografica
Continente #
NA - Nord America 5.640
EU - Europa 3.513
AS - Asia 3.206
SA - Sud America 364
Continente sconosciuto - Info sul continente non disponibili 108
AF - Africa 50
OC - Oceania 6
AN - Antartide 1
Totale 12.888
Nazione #
US - Stati Uniti d'America 5.510
IT - Italia 1.632
HK - Hong Kong 1.497
FI - Finlandia 1.199
SG - Singapore 818
CN - Cina 356
BR - Brasile 262
VN - Vietnam 192
RU - Federazione Russa 150
FR - Francia 94
DE - Germania 92
IN - India 73
IE - Irlanda 64
KR - Corea 62
CA - Canada 60
NL - Olanda 53
GB - Regno Unito 50
SE - Svezia 49
AR - Argentina 47
BD - Bangladesh 40
JP - Giappone 37
MX - Messico 25
PL - Polonia 21
AT - Austria 18
ES - Italia 18
UA - Ucraina 17
EC - Ecuador 16
TR - Turchia 16
CO - Colombia 15
PK - Pakistan 15
IQ - Iraq 14
CH - Svizzera 13
ID - Indonesia 13
ZA - Sudafrica 10
EG - Egitto 9
HR - Croazia 9
JM - Giamaica 9
PH - Filippine 9
TT - Trinidad e Tobago 9
TN - Tunisia 7
UZ - Uzbekistan 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
JO - Giordania 6
MA - Marocco 6
PT - Portogallo 6
ET - Etiopia 5
LT - Lituania 5
MY - Malesia 5
OM - Oman 5
SA - Arabia Saudita 5
CL - Cile 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
HN - Honduras 4
NI - Nicaragua 4
PE - Perù 4
PY - Paraguay 4
BE - Belgio 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
IR - Iran 3
PS - Palestinian Territory 3
SN - Senegal 3
UY - Uruguay 3
AL - Albania 2
BG - Bulgaria 2
BH - Bahrain 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
GY - Guiana 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
NP - Nepal 2
PR - Porto Rico 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AO - Angola 1
AQ - Antartide 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
GP - Guadalupe 1
HT - Haiti 1
HU - Ungheria 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
ML - Mali 1
Totale 12.769
Città #
Dallas 2.850
Hong Kong 1.493
Helsinki 1.182
San Jose 540
Singapore 401
Milan 329
Chandler 231
Ashburn 222
Rome 192
Council Bluffs 177
Princeton 149
Beijing 109
Naples 74
The Dalles 73
Ho Chi Minh City 70
Lauterbourg 70
Moscow 63
Dublin 62
Santa Clara 60
New York 57
Los Angeles 53
Ann Arbor 52
Munich 45
São Paulo 39
Salerno 36
Tokyo 34
Wilmington 34
Hanoi 31
Bari 29
Turin 28
Phoenix 27
Amsterdam 26
Houston 26
Figino 25
Genoa 24
Seattle 23
Stockholm 22
Montreal 21
Warsaw 19
Bologna 18
Orem 18
Palermo 18
Andover 17
Brooklyn 17
Chennai 17
Columbus 17
London 17
Florence 16
Jacksonville 16
Nuremberg 16
Seoul 15
Denver 14
Dong Ket 14
Fisciano 14
Boston 13
Verona 13
Atlanta 12
Mumbai 12
Turku 12
Woodbridge 12
Catania 11
Frankfurt am Main 11
Boardman 10
Cava de' Tirreni 10
Las Vegas 10
Toronto 10
Chicago 9
Da Nang 9
Mexico City 9
Pune 9
Albignasego 8
Charlotte 8
Padova 8
Rio de Janeiro 8
San Francisco 8
Venice 8
West Jordan 8
Belo Horizonte 7
Cagliari 7
Cinisello Balsamo 7
Guangzhou 7
Sarno 7
Taranto 7
Thái Nguyên 7
Asti 6
Baghdad 6
Buenos Aires 6
Buffalo 6
Haiphong 6
Jakarta 6
Lahore 6
Lamezia Terme 6
Messina 6
Modena 6
Napoli 6
Poplar 6
Quito 6
Rimini 6
Sydney 6
Acerra 5
Totale 9.614
Nome #
058 Oxidative stress in atopic dermatitis and cardiovascular disease: urinary biopyrrins as possible biomarker 4.000
Eruzione cutanea dopo vaccino SARS CoV-2 in paziente psoriasico trattato con MTX 916
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY Study 497
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis 452
Prevalence, Features and Degree of Association of Oral Lesions in COVID-19: A Systematic Review of Systematic Reviews 257
Psoriasi eritrodermica: rapida efficacia di bimekizumab 218
An acute spondyloarthritis during successful treatment with dupilumab for severe atopic dermatitis 176
Psoriasi e salute del cavo orale: un nesso da non sottovalutare. I primi risultati di uno studio clinico osservazionale 158
AUF-1 and skin inflammation: atopic dermatitis and psoriasis 153
Sicurezza ed efficacia di Apremilast in paziente psoriasico oncologico in terapia con pembrolizumab 145
Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection 139
Psoriasis and bone damage: the role of phosphodiesterase 4 in the pro-osteoclastogenic process induced by skin inflammation. 137
Cannabidiol exerts multitarget immunomodulatory effects on PBMCs from individuals with psoriasis vulgaris 132
Understanding the role of haptoglobin in psoriasis: Effects of ultraviolet B 131
Anti-tumor necrosis factor-α therapy in the management of psoriasis and B-chronic lymphocytic leukemia 119
Atopic dermatitis: Epidemiology and clinical phenotypes 119
Presence of BAG3 protein in serum samples from patients affected by psoriasis 116
Interleukin-33: increasing role in dermatological conditions 116
Photosensitivity and cancer immune-targeted therapies 115
Confronto del profilo di efficacia, sicurezza e compliance tra Apremilast, NB-UVB e MTX nei pazienti psoriasici: i primi risultati di uno studio osservazionale multicentrico italiano 113
RAST: Clinical applications 110
Anti-IL-17 therapy rapidly decreases osteoclast activity in psoriatic patients: A novel quality in addition to its efficacy and safety 109
Carcinoma basocellulare con invasione perineurale: gestione terapeutica 105
Flash-pumped pulsed dye laser for vascular skin lesions: our experience and an overview of the literature 104
A preterm infant with benign neonatal hemangiomatosis and persistent patent ductus arteriosus: A curious comorbidity 102
Oral Human Papillomavirus Benign Lesions and HPV-Related Cancer in Healthy Children: A Systematic Review 94
AUF-1 and skin inflammation: atopic dermatitis and psoriasis 94
Lenalidomide-induced psoriasis in a refractory multiple myeloma patient successfully treated with narrowband ultraviolet B 93
"Pro-osteoclastogenesis march" is induced by cutaneous pro-inflammatory mediators 93
Oral Lesions and Oral Health-Related Quality of Life in Adult Patients with Psoriasis: A Retrospective Chart Review 92
121 Oxidative stress in atopic dermatitis: urinary biopyrrins as possible new biomarker 92
Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real-world study 91
Paraoxonases and psoriasis: negative imbalance of anti--oxidant endogenous mechanisms 90
Secukinumab e popolazioni speciali: focus su tubercolosi latente ed epatite virale: studio retrospettivo 89
Apremilast, NB-UVB e MTX: confronto del profilo di efficacia, di sicurezza e capacità di modulazione dell’infiammazione sistemica nei pazienti psoriasici. Studio osservazionale di coorte prospettico 88
The laboratory role in the assessment of sensitization and irritation potential of cosmetics 86
Psoriasiform dermatitis during dupilumab treatment in atopic patient resolved after combo-therapy with methotrexate 85
IL-33 is regulated by TNF-α in normal and psoriatic skin 84
A journey into psoriasis: From the adipose tissue to the skin 84
European Task Force on Contact Dermatitis statement on coronavirus disease-19 (COVID-19) outbreak and the risk of adverse cutaneous reactions 83
Cutaneous Eruption after SARS-CoV-2 vaccine in psoriatic patient treated with methotrexate 82
PDE4 Inhibition Reduced Osteoclast Differentiation in Psoriatic Patients 80
Guselkumab for the treatment of psoriasis 79
Hair whitening in a patient with psoriasis during failure of adalimumab treatment reversed by ixekizumab 78
Clinical predictors of psoriatic arthritis and osteoclast differentiation 78
From the skin to the bone: Pro-osteoclastogenesis inflammatory march 78
A potential prognostic test for bone erosion development in patients with cutaneous predictive sites for psoriatic arthritis 78
A severe relapse of pemphigus vulgaris after SARS-CoV-2 vaccination 77
IL-26 in allergic contact dermatitis: Resource in a state of readiness 77
The role of the dermatologist in the immune-mediated/allergic diseases – position statement of the EADV task force on contact dermatitis, EADV task force on occupational skin diseases, UEMS-EBDV subcommission allergology and European Dermatology Forum 75
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study 73
Psoriasis, cardiovascular events, and biologics: Lights and shadows 71
Italian National Registry of Alopecia Areata: an epidemiological study of 699 Italian patients 70
Polymorphic light eruption: What's new in pathogenesis and management 70
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis 70
Human Microbiome: Composition and Role in Inflammatory Skin Diseases 69
The important role of interdisciplinary collaboration in the management of a melanocytic skin lesion 69
Farmaci biologici e small molecules in dermatite atopica: confronto su efficacia e sugli effetti nella gestione del prurito 66
Disseminated mucocutaneous Candida infection during anti IL-17A therapy in a psoriatic patient 64
IL-26: A new actor in allergic contact dermatitis 63
Immuno-Pathogenesis of Chronic Inflammatory Skin Diseases: Novel Molecular Targets and Biomarkers 62
The effects of skin psoriasis inflammation on adipose tissue-derived mediators and viceversa 62
Misurazione dinamica degli inquinanti in pazienti affetti da dermatite atopica 59
Dupilumab therapy reduces urinary biopyrrin levels in atopic patients: a new possible biomarker of oxidative status in atopic dermatitis 58
Pro-osteoclastogenesis march is enhanced by cutaneous pro-inflammatory mediators 58
Sociodemographic, clinical and therapeutic factors as predictors of life quality impairment in psoriasis: A cross-sectional study in Italy 57
Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study 56
Photodermatoses and Skin Cancer 56
Studio osservazionale descrittivo per la valutazione della prevalenza della psoriasi nei pazienti adulti dislipidemici in terapia monoclonale con anti-PCSK9 55
Ultrasonography in the management of a recurrent and eruptive lobular capillary hemangioma and resolution with intense pulsed light 55
Systemic inflammation: psoriasis as a model…in Naples 55
Guselkumab e psoriasi in sedi difficili: efficacia ed impatto sulla qualità di vita in pazienti naive o bio experienced 54
New insights into mechanism of Notch signaling in hidradenitis suppurativa 54
UVB-induced p53 is reduced by a mixture of natural extracts 54
Notch dysregulation and hidradenitis suppurativa, psoriasis, atopic dermatitis and lichen planus: let's talk about Numb 52
Oxidative Stress in Atopic Dermatitis and Possible Biomarkers: Present and Future 51
Efficacy, tolerability and patient's satisfaction for the treatment of moderate to severe plaque psoriasis with apremilast in the real-life setting of Campania region, Italy 50
Psoriasi e terapia con guselkumab: panoramica 2022 dal centro prescrittore AOU Salerno 49
Oral Diseases During Systemic Psoriatic Drugs: A Review of the Literature and Case Series 46
Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future 46
Novel interactions among ultraviolet B, skin and adipose tissue 46
Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real‐world study 44
The role of the RNA-binding protein AUF-1 in chronic inflammatory skin diseases and cellular senescence 44
Letters to the editor 41
Dermatite atopica e stress ossidativo: nuovi biomarker 38
Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study 28
Cutaneous Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Cohort Study of Clinical Spectrum and Treatment Patterns 14
Totale 12.888
Categoria #
all - tutte 35.993
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.993


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022246 0 0 0 20 30 2 0 11 21 5 40 117
2022/2023544 55 56 27 74 27 102 6 53 87 15 27 15
2023/2024541 23 54 39 26 35 45 28 46 18 66 54 107
2024/20251.533 65 36 115 137 79 187 169 86 240 88 145 186
2025/20268.930 252 1.644 2.755 316 478 243 648 144 1.389 463 162 436
2026/2027891 207 112 289 283 0 0 0 0 0 0 0 0
Totale 12.888